Bergamo Lymphoid Cancer Registry
1 other identifier
observational
6,000
1 country
1
Brief Summary
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 23, 2017
CompletedFirst Submitted
Initial submission to the registry
April 20, 2017
CompletedFirst Posted
Study publicly available on registry
April 27, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 23, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 23, 2037
March 6, 2024
March 1, 2024
10 years
April 20, 2017
March 5, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival
Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics
20 years
Secondary Outcomes (3)
Disease-free survival
20 years
Progression-free survival
20 years
Biological correlative studies
20 years
Study Arms (3)
Hodgkin lymphoma
Non-Hodgkin lymphoma
Myeloma
Interventions
Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Eligibility Criteria
Patients eligible for this study are patients with a diagnosis of lymphoid cancer in charge of the Hematology and Bone Marrow Transplant Unit "Ospedale Papa Giovanni XIII" of Bergamo.
You may qualify if:
- Male or female patients 18 years or older
- Written informed consent
- Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
You may not qualify if:
- \- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII
Bergamo, 24127, Italy
Biospecimen
Biological specimens include peripheral blood, serum, plasma, bone marrow, lymph node, normal or disease-infiltrated tissues
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alessandro Rambaldi, MD
A.O. Ospedale Papa Giovanni XXIII
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 20 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
April 20, 2017
First Posted
April 27, 2017
Study Start
March 23, 2017
Primary Completion (Estimated)
March 23, 2027
Study Completion (Estimated)
March 23, 2037
Last Updated
March 6, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share